ARK Investment Management LLC Lowers Stake in Alnylam Pharmaceuticals, Inc. (ALNY)
ARK Investment Management LLC cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,276 shares of the biopharmaceutical company’s stock after selling 948 shares during the period. ARK Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $421,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in ALNY. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $148,000. Westpac Banking Corp purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $202,000. Prudential Financial Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $215,000. CIBC Asset Management Inc purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $221,000. Finally, Neuberger Berman Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $229,000. 94.25% of the stock is owned by institutional investors.
Several analysts have recently issued reports on the stock. Morgan Stanley reissued an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. BidaskClub cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 16th. Needham & Company LLC boosted their price objective on shares of Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday. BMO Capital Markets reissued an “outperform” rating and set a $134.00 price objective (up from $99.00) on shares of Alnylam Pharmaceuticals in a research note on Friday. Finally, J P Morgan Chase & Co reissued a “hold” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, June 26th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $93.11.
Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded up 0.78% during trading on Friday, reaching $113.80. 2,339,648 shares of the company’s stock were exchanged. The company’s 50-day moving average is $81.14 and its 200-day moving average is $69.12. The company’s market capitalization is $10.44 billion. Alnylam Pharmaceuticals, Inc. has a 1-year low of $31.38 and a 1-year high of $118.40. Alnylam Pharmaceuticals also was the target of some unusual options trading activity on Wednesday. Traders purchased 30,530 call options on the company. This represents an increase of 937% compared to the average volume of 2,944 call options.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm had revenue of $15.93 million during the quarter, compared to analyst estimates of $23.86 million. During the same quarter in the previous year, the business posted ($1.05) earnings per share. The business’s quarterly revenue was up 82.9% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post ($5.19) earnings per share for the current fiscal year.
In related news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “ARK Investment Management LLC Lowers Stake in Alnylam Pharmaceuticals, Inc. (ALNY)” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/ark-investment-management-llc-lowers-stake-in-alnylam-pharmaceuticals-inc-alny/1582899.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.